Baird maintains Nike stock rating on design patent analysis

Baird reiterated Neutral on Nike with a $36 price target versus a $34.61 share price, saying its review of roughly 20 years of U.S. design patents—subject to a 15-month-or-longer lag—shows 2024 filings about 21% below the 2019–2022 pace. Lifestyle activity fell more sharply, and a rebuild is not yet visible in early 2025 filings; Nike’s revenue declined 1.2% over the last 12 months and its stock is down 44% year-to-date. Recent fiscal 2027 results included the first revenue miss in seven quarters, while management cited challenges in Greater China and EMEA and revenue was projected to decline by a high single-digit percentage. Analyst views remain mixed, with Baird calling near-term risk/reward balanced.

Analysis

The actionable signal is not the patent count itself; it is the risk that Nike’s product pipeline cannot refresh lifestyle demand quickly enough to offset weakness in performance categories. Patent filings are a lagging, imperfect proxy for launch quality and commercial sell-through, so they should not be treated as a standalone forecast. The more consequential near-term mechanism is revenue weakness alongside a still-unproven rebuild: discounting to clear older product could erode gross margin and brand positioning even if current margin results hold up.

Over the next 1–3 months, watch revenue and regional sell-through, inventory/promotional intensity, and whether guidance stabilizes. A further deterioration in China or EMEA would make the reset deeper; a revenue recovery without heavier promotions would challenge the bear case. Over 6–18 months, successful launches could restore growth, but design work visible in filings today has a substantial commercialization lag. The consensus split is not a catalyst by itself, and the reported share-price decline may already discount part of the reset; absent valuation and channel data, avoid treating the patent evidence as a precise earnings estimate. The headline’s reference to a broader bull market is not supported by the Nike-focused body, so no market-wide inference is warranted.

Key Decisions for Investors

• Do not add to NKE solely on apparent valuation or the possibility of a future lifestyle rebuild. Wait for evidence in sell-through and revenue that newness is converting into demand without increased promotions.
• For the next earnings cycle, track regional revenue, inventory and gross-margin commentary together. A renewed revenue miss or margin slippage tied to promotions would confirm downside risk; sequential stabilization with clean sell-through would weaken it.
• Consider a relative underweight in NKE versus stronger athletic/apparel peers such as Adidas or Deckers only if upcoming results confirm continued share or demand weakness. Size against peer valuation and channel data, which are not provided here; do not assume the patent series alone establishes a relative short.
• Revisit the thesis over a 6–18 month horizon as rebuilt products reach market. Falsification: sustained revenue improvement across lifestyle and performance, stable margins without elevated discounting, and improving China/EMEA trends.